Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07829926) titled 'Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer' on Sept. 11.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: First Affiliated Hospital of Wenzhou Medical University

Condition: Hepatocellular Carcinoma (HCC)

Intervention: Drug: Lenvatinib Drug: Tislelizumab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: November 2026

Target Sample Size: 120

To know more, visit https://clinicaltrials.gov/study/NCT07829926

Discla...